16F Beike Building, 18 Keyuan Rd., High-Tech Park South Area, Nanshan District, Shenzhen, China 518057
Beike is a Chinese biotechnology company with main offices in Shenzhen (near Hong Kong) and Taizhou. Beike's stem cell research and clinical applications were developed starting in the 1990s. Over 60 PhDs from leading Chinese universities contributed to advancing Beike's treatment technologies. Many of Beike's scientists also have experience at leading Western universities, including Stanford, the University of Minnesota, and UCLA.
Since 2005, Beike has been providing adult stem cell treatment protocols for more than 22,500 including patients coming from 40+ countries such as USA, Canada, England, Australia South Africa, France, Germany, Spain, Portugal, Italy, Belgium, Poland, Romania, Brazil, Mexico, Colombia, Argentina Korea, China, Thailand, India, Cameroon, Algeria, Tunisia, Morocco and more. Beike Biotech has a multicultural team who is able to communicate in 15+ languages.
If you are looking for a reliable partner who is very concerned about the way the stem cells are collected and safe kept you know than Beike is the answer. Some of the laboratories are located in the research departments of hospitals while others are located directly inside government blood banks. Because we are so concerned with the safety Beike also has its own bank for the storage of stem cells in partnership with the regional government in China. All equipment in the banks and laboratories is compliant with nowadays standards.
Treatments and procedures
Beike provides treatment protocols that not only include multiple stem cell injections but also extensive rehabilitation programs in order to provide real chances of improvement for patients diagnosed with various neurological and neuro-muscular conditions, as well as for auto-immune diseases and more.
While most companies around the world relie on offering short treatment duration, very limited amount of stem cells (through one or two injections at most) and do not provide rehabilitation therapies whatsoever, we believe that a very comprehensive approach is required to truly unlock the regenerative potential of stem cells and guide our patients towards a better future.
Stem cells help your body with increasing some of the vital functions that are affected by the particular disease, such as: improving the effective conduction of intercellular electrical signals and transduction, neo-angiogenesis (the growth of blood vessels resulting in increased blood flow to damaged areas), reducing cell death, immune system regulation and stimulation of growth of the patient’s own stem cells.
Samples of key conditions that can be improved through stem cell treatment: (SMA)Spinal Muscular Atrophy, Cerebral Palsy, Autism, Ataxia. Liver Cirroshis, Multiple Schlerosis, Muscular Distrophy.
In the above mentioned treatments we use the following type of cells: Umbilical Cord Blood-Derived Stem Cells (UCBSC), Umbilical Cord-Derived Stem Cells (UCMSC) and Autologous Bone Marrow Stem Cells (BMSC). These can be injected intravenous, by lumbar puncture or by local injections.
Why choose us?
Beike Biotechnology is the world leader in providing stem cell treatments for patients with major injuries and diseases. Our treatments have been safely administered to over 22.500 patients, combining the most intensive stem cell protocols available with expansive support therapy including rehabilitation and acupuncture.
Our Promise Of Service and Care.
Our International Department was created with the specific purpose of making communication as easy as possible for inquiring international patients.
Upon arrival at the airport, you will be received by an English-speaking patient coordinator immediately outside baggage claim and brought to the hospital. These affiliated medical centers are amongst the best in their respective countries.
While the treatment itself may last several weeks, its main benefits frequently become evident after the patient has returned home. In order for our medical staff to monitor your progress, it is very important for us to maintain contact with each patient.
Beike Biotechnology has been cooperating with various hospitals across Asia, in countries such as Thailand and China. Although these locations may sound far from your home country, our treatment centers allow for an affordable but nevertheless very extensive treatment. Our affiliated treatment centers not only provide stem cell administration but also a combination of supportive therapies adapted to each patient's specific needs. At Beike Biotechnology, we believe that stem cells need intensive and continuous stimulation to deliver their full potential. We are proud to work with modern hospitals and experienced doctors that deliver for us what we consider to be the world's most extensive stem cell treatment for a wide range of medical conditions.
If you want to know more about the treatments and procedures offered by Beike Biotechnology, please contact us!
The company was founded with capital from Beijing University, Hong Kong University of Science and Technology, and Shenzhen City Hall. The formation of the company was also supported with grants from the China State National Fund.
Since that time, additional capital has been provided by a variety of Chinese venture capital firms.In total, Beike has received over US$6 million in Chinese government grants including a grant for a joint laboratory in Shenzhen with Tsingua University to focus on the study of stem cell reprogramming.
Beike‘s head office is located in Shenzhen but the company also has offices in Beijing, Nanjing, Taizhou, and Qingdao.
The first patient (happening to be diagnosed with ALS) to be treated with Beike processed cells was in 2001. Over 200 patients participated in studies and were treated between 2001 to 2005 in order to determine treatment efficacy for a small number of end-stage and otherwise incurable diseases. Beike was incorporated in July 2005 and has since provided partner hospitals with stem cells for the treatment of over 9000 patients.
Beike currently maintains 25 laboratories for both research and cell processing for clinical use and has received over US$6 million in government grants. We even recently had the honor of welcoming Chinese Premier Wen Jiabao for a tour of our Shenzhen facilities in August of 2010.
Our research for future treatments is focused mainly on iPS technology in partnership with various leading scientific groups including Tsinghua Unversity. Beike’s scientists and partners have authored nearly eighty publications in Chinese scientific journals as well as ongoing clinical studies since our first ALS trial program in 2001. We very much welcome cooperation with international partners to help verify the effectiveness of our treatments and protocols and to license other technologies for use throughout our network of twenty-seven hospitals.
Beike As A Research Organization
Beike is a dedicated research organization. Our vigor for helping patients extends far beyond simply using stem cells for clinical treatments based on other’s research. It extends into actual scientific research into cell technologies and Beike has been one of the world leaders in this important research.
This allows Beike’s treatment protocols and stem cell processing to not only be guided by 3rd party research, but also our own. Beike has almost 50 published peer-reviewed research papers in scientific journals around the world (such as Nature) and has spent tens of millions over the past decade on scientific laboratories and cell research.
Beike As A Treatment Partner
Since 2005, Beike has provided partner hospitals with stem cells for the treatment of over 9000 patients. Beike currently provides more than 30 hospitals with umbilical cord, cord blood, and bone marrow-derived stem cells for the treatment of neurological and vascular diseases. Being the provider, Beike is able to maintain full oversight over cell manufacturing, from the testing of blood products, to cell processing at our laboratories, to delivery of the cells for clinical use. This ensures cell safety and quality.
Beike also works closely with our partner hospitals in the evolving of treatment protocols and patient care. Each partner hospital maintains Beike International Department staff to assist patients both with the treatment and with general needs during the hospital stay.
If you want to know more about the treatments and procedures offered by Beike Biotechnology, please contact us!
A very quick look at the basics of the treatment. Please keep in mind that stem cell treatment is not a cure and has not yet been approved as a treatment by the Food and Drug Administration of the United States. It is a treatment that can help to relieve various symptoms associated with neurological and vascular conditions.
Our Stem Cells
Most cells in the body have a specific function in particular organs, such as the liver, skin or brain. Stem cells are relatively undifferentiated and still have the ability to develop into different types of cells and perform different functions. The most notable characteristic of a stem cell is its ability to reproduce a completely new, normal, and even younger cell. As a result, people can use their own stem cells, those from a donor, or stem cell-derived tissues or organs to replace ill or aging tissues or organs. This permits treatment of a wide range of diseases and injuries, many of which cannot be treated with traditional medical methods.
What Type Of Stem Cells Are Used:
Our Cell Processing and Safety Standards
Cord Blood Collection and Two Step Testing
It is a common practice in China for mothers to voluntarily donate the umbilical cord blood from the birth of their healthy full-term children. Every woman who enters a hospital in China to give birth is automatically tested for all major diseases including hepatitis and HIV. Detailed family histories are also collected from each mother prior to donation. This represents the first step of the screening process for donated cord blood. Only women who have been fully screened and found to be completely healthy are allowed to donate umbilical cord blood.
The second step in the screening process occurs when each sample is tested by blood bank technicians. Once the blood has been tested negatively for communicable diseases, it is transferred to our laboratories and officially becomes the property of Beike Biotechnology. From this stage, Beike is responsible for each and every sample that is processed and provided to patients.
Obtaining the cord blood serum and preparing the stem cells for culturing is accomplished by separating the desired components from the cord blood. The blood cells need to be removed from the blood serum and stem cells so as to not interfere with future injections. A centrifuge is used to separate the serum and stem cells from the red cells and platelets. This is a highly refined and specialized separation process. After separation has been completed, the stem cells are removed for culture and the serum, usually 25-35 ml in volume, is set aside for direct translate into our patients.
The stem cells derived from each umbilical cord blood unit are seeded into a flask filled with culture medium. The flasks are placed in a sterilized, temperature and humidity controlled incubator. The stem cells are expanded in the culture medium and any blood cells remaining will be separated at this stage. Once the culturing is complete, the desired stem cells with a quantity more than 50,000,000 are harvested for transplantation.
Final Check and Cataloging of Units
All batches of stem cells undergo final testing. During this process they are also checked for quantity and quality. Once the stem cells are deemed safe, each unit is placed into either a sterile vial or a sterile IV bag for future transplantation. All products are individually cataloged and tracked while in transit. our cell transplants take place three days a week, on Mondays, Wednesdays, and Fridays.
Packing and Transport
Three days a week, our lab technicians prepare the cell products to the transferred to the treatment center. Each patient is assigned his or her cataloged sample and this information is tracked during transport, receipt, and transplant of each unit. In some cases the labs are located in the same hospital as the treatment center. In others, they are located in the same city or province. In this case, cells are transported to the center on the day of transplant. All Beike stem cell packets are always under the supervision and care of Beike employees.
How are the stem cells injected?
During treatment, Beike’s partner hospitals provide patients with daily rehabilitation sessions in additional to the stem cell injections. We believe this rehabilitation is instrumental in providing the greatest possibility and range for improvement. Most patients undergo two sessions a day for a total of two or three hours. Rehabilitation is provided five or six days each week (excluding conflicts with the injection schedules, Chinese holidays, or poor patient health). This program consists of a tailored mix of physical therapy, occupational therapy, acupuncture, manipulation, activities of daily life (ADL) education, and massage therapy. Our therapists will decide what combination is appropriate for each individual. Some diseases and injuries require very specialized rehabilitation programs and an on-site evaluation is completed upon arrival. This is included in the treatment package and our scientists and rehab therapists both believe that physical stimulation aids the stem cells in their work. For ailments such as spinal cord injuries, cerebral palsy, and brain injuries, it is recommended that the patient continue his or her exercises as much as possible for at least three months following treatment. If you already have a customized physical therapy regimen or a highly specialized therapy program you might like to continue, please bring video documentation to share with our therapists. Our therapists can assist you with this therapy or they may recommend a complementary regimen.
What are possible treatment locations?
What is the general treatment length?
The above are general guidelines and depend upon the doctors’ medical review.
Below are pages featuring some of the key conditions that have previously received treatment (please note that these are not the only diseases that can be treated and is just a sample).
What is included in the treatment?
How is contact continued after returning home?
Frequently Asked Questions
What if the stem cells injected at the hospital are not the same as the ones that were initially recommended in the confirmation email sent to patients. In GZ many patients (if not all) get UCMSC instead of UCBSC, what is the difference between those 2 types of cells?
Answer: For all the international patients the recommended type of stem cells is mentioned in the confirmation email based on Beike treatment protocols, but the final decision for the types of stem cell should be made by local doctors
GZ Center is optionally providing Nerve Growth Factors. How this can help for the treatment? I think that doctors in GZ often recommend extra NGF injections to patients, so we should inform patients going to GZ about this possibility. There is obviously an extracost and I think that's not really nice to inform them about that when they are already at the center (I believe it is 1 intramuscular injection per day during 10 days for short treatment protocole and 20 days for long protocole. 1 injection is about 130 rmb)
Answer: GZ center is using a new nerve growth factor, named as Shenjie, which is also widely used in other countries. As for the extracost, we can discuss with local doctors and ask them to clearly let patients know when they recommend NGF to our international patients, and our patients can decide if they still want to receive the treatment.
What is the difference between the results of autologus bone marrow stem cells injection and the UCBSC?
Answer: It is very hard to give an answer. First, there are very few academic studies forthis issue. Second, also very few International patients have been treated with Autologous Bone marrow stem cells by Beike and we don't have enough follow up data.
Why patients with negative blood factor have to take UCMSC?
Answer: Most of the donors of cord blood are Rh positive and UCBSC even after careful purification may contain donor blood products. Once cord blood derived stem cells (from an Rh positive donor) are injected into an Rh negative patient there are more chances of an incompatibility reaction (hemolytic reaction) so Beike do not recommend UCBSC for Rh negative patients. UCMSC are pure cells and do not contain donor blood products so it is safe for Rh negative patients to get UCMSCs.
If a patient gets sick right after the treatment then our treatment loss the efficacy?? If so the how much?
Answer: Based on research publications stem cells are believed to be attracted by cytokines and other inflammatory mediators which are present at the injury site. We believe that any injury or infection other than the Primary Diagnosis may draw stem cells and may result in less number of stem cells available for the actual condition so it is strongly recommended for the patients to try to avoid any infection or sickness right before or after the treatment. There is no way, at present, to know the degree of treatment ef icacy af ected by an illness or infections.
Could you explain the procedure of application of the retrobulbar injection?
Answer: The procedure of retrobulbar injection as below: 1st Step The patient takes a lying position or sitting position, 3% tincture of iodine and 75% alcohol are carefully applied to disinfect the skin from the lower eyelid margin to the lower orbital rim, respectively. 2nd Step A sharp edged rounded tipped needle is inserted vertically 2 millimeters in the quadrant between the outside 1/3 inside 2/3 the lower orbital rim (if the injection is done from conjunctival sac site, the lower eyelid is pulled open before injection and then the needle is inserted into the lower conjunctival sac at the same site). 3rd Step The needle is passed the aequator of the eye globe and then directed towards the upper nasal site until it is about 3 centimeter in depth. The operator need push back the syringe to make sure no laceration of the blood vessels and then injects the stem cell into the retrobulbar space. 4th Step After the injection, the needle is gently removed and then the globe should beintermittently compressed with disinfected bandages for several minutes to prevent hemorrhage.
Are we still on the experimental trial or we have already scientifically probed all our treatments?
Answer: Still on the clinical trial stage for more scientific evidence to support stem cell treatment as an innovative therapeutic strategy.
Is the CTGuided intraspinal injection risky? Why don't we use it for all SCI patients?
There are some risks associated with every medical and surgical procedure so do with the CT guided intra spinal cord injection. On the other hand, we also found that CT guided intra spinal cord injection was performed successfully for stem cell treatment on the basis of 11 patients’ information from SJZ treatment center. This injection is only recommended for complete SCI patients or incomplete SCI patients with severe condition in order to balance the risks and benefits associated with this injection.
Are we going to use Nerve Growth Factors in Beijing? CTGuided Injections? RBI?
Answer: We need to wait and see what BJ can provide to our patients.
If you want to know more about the treatments and procedures offered by Beike Biotechnology, please contact us!
CEO and Chairman - Dr. Sean Hu
Dr. Sean Hu, Ph.D; Director of Shenzhen R&D Center of Stemcell Engineering and Technology, Director of Beike Stemcell Research Institute of China Medical City, Director of Shenzhen Beike Cell Engineering Research Institute.
Dr. Sean Hu received his Ph.D from the Department of Biochemistry and Biophysics at Gothenburg University in Sweden in 1998. After spending several years in Sweden he moved to Canada to do his post-doctoral research in the Department of Biochemistry and Molecular Biology at the University of British Columbia. In 2001, he moved back to China, where continuous breakthroughs in the stem cell research field inspired him to support various stem cell research institutions in China. Since then, he has continued to focus his passion and energy towards the progress of stem cell research.
In June 2005, Dr. Sean Hu founded Shenzhen Beike Cell Engineering Research Institute, whose primary mission is to act as a platform for the advanced research of stem cell technology. In 2008, Dr. Sean Hu was listed in the National Annual "Thousand-Person Program" by the Organization Department of the Communist Party of China (CPC) Central Committee for his outstanding achievements in the field of stem cell research.
CSO - Dr. Susan Jiang
Dr. Susan Jiang began her career path as a physician in the field of otorhinolaryngology, specializing in head and neck (ENT-HN) surgery. After receiving her Ph.D. in China, she completed post-doctoral work in the Department of Physiology Biophysics at the University of Arkansas in 2002. In 2005, Dr. Jiang moved to the Pediatrics Department of Stanford University where she investigated the therapeutic potential of stem cells in neo-natal respiratory diseases and developed wound healing models based on stem cell technologies. After nearly three years at Stanford, she became Scientific Director at Escape Therapeutics in the U.S., managing their science team as they developed products based on genetically engineered human stem cells and beta cells for diabetic-related disorders. Dr. Jiang joined Beike as CSO in 2009.
iPS Research Director - Dr. Li Tao
Dr. Tao comes to Beike with over 20 years of research experience in genetics, epigenetics, cell and stem cell biology, molecular biology, cancer biology, and protein chemistry. He was most recently a senior research scientist at Stanford University's School of Medicine. During his six years at Stanford, he authored or co-authored 22 papers in peer-reviewed journals including Science, Human Molecular Genetics, Cancer Research, and Genomics. Before Stanford, he earned his Ph.D. at Tokyo University and spent nine years in Japan working on genetics and genetic engineering, publishing articles in 16 international, peer-reviewed, journals.
Beike Biotechnology Upgrades Its Processing and Cryopreservation Technology to Expedite Advancements in Stem Cell Therapies
Wednesday, 16 March 2011 10:07
Beike and ThermoGenesis Intend to Establish a "Center of Excellence" Showcase in Taizhou City
TAIZHOU, China, March 16, 2011 /PRNewswire-Asia/ -- Beike Biotechnology Co. Ltd. ("Beike"), China's leading stem cell research and regenerative medicine company, announced an agreement with USA-based ThermoGenesis Corp. to employ new, cutting edge stem cell processing and storage technology across its adult stem cell collection, processing, and archive platform.
Under the arrangement, which underscores Beike's strategic commitment to upgrading its current technology and clinical research capabilities, Beike becomes the first company in the People's Republic of China to secure the rights to the AXP and BioArchive Cord Blood systems. AXP® is a proprietary family of automated devices used for the processing of cord blood; the BioArchive® System is an automated cryogenic device used to archive cord blood stem cell units for transplant.
New Research Demonstrates Safety of Cord-blood-derived Stem Cell Treatments
Friday, 03 September 2010 11:16
Beike Biotechnology and Medistem, Inc. Report on 114 Patients Treated With Novel Cord Blood Stem Cell Protocol; New Approach Opens Door to Expanded Uses of Cord Blood Stem Cells
SHENZHEN, China, Sept. 2 /PRNewswire-Asia/ -- In a new peer-reviewed article published by the Journal of Translational Medicine, scientists from Beike Biotechnology, China's leading stem cell research and regenerative medicine company, and Medistem, Inc., reported positive safety data in 114 patients who were treated by doctors at Nanshan Affiliated Hospital of Guangdong Medical College (Shenzhen Nanshan Hospital) in Shenzhen using Beike's proprietary cord blood stem cell transplantation protocol.
The report aims to serve as an "expanded Phase I" study, with efficacy data to be published in a subsequent paper. It describes biochemical, hematological, immunological, and general safety profiles of patients with neurological diseases who were observed from between one month to four years after treatment. No serious treatment-associated adverse effects were observed.
New Study Demonstrates Improvements in Lupus Patients Receiving Stem Cell Therapies
Tuesday, 08 June 2010 08:25
Lupus study shows promising results using umbilical cord mesenchymal stem cells.
NANJING, Jiangsu, China, June 7, 2010 /PRNewswire-Asia/ -- A new study shows that umbilical cord mesenchymal stem cell transplant (UC-MSCT) may improve symptoms and biochemical values in patients with severe refractory systemic lupus erythematosus (SLE).
In research published online (ahead of print) May 6, 2010 in Arthritis & Rheumatism, lead author and Director of Rheumatology and Immunology at Nanjing University Medical School's renowned Drum Tower Hospital Dr. Lingyun Sun and colleagues report on 16 patients with severe SLE that did not respond to standard treatments. All 16 patients received stem cell transplants. Ten patients completed at least 6 months of follow-up and 2 patients were followed for more than 2 years. There was no treatment-related mortality or other adverse event during or after UC-MSCT, according to the article.
Beike Biotechnology Opens First Chinese Rehabilitation Center in Romania
Wednesday, 21 July 2010 09:53
New Center Integrates Traditional Chinese, Romanian and Western Therapies
CAMPINA and PRAHOVA, Romania, July 20 /PRNewswire-Asia/ -- Beike Biotechnology Co. Ltd., one of the world's leading biotechnology companies focusing on adult stem cell therapies, opened Romania's first rehabilitation center to use traditional Chinese-style rehabilitation techniques in Campina today.
The new Romanian center is Beike's first stand-alone rehabilitation facility in the world. Physical rehabilitation is a key component of Beike's stem cell therapy protocols which are utilized by leading hospitals throughout China. In conjunction with each one-month stem cell treatment cycle, most patients undergo extensive physical therapy and rehabilitation in an effort to enhance the effects of the stem cells. Chinese patients are able to continue with the rehabilitation after the treatment is completed, but often overseas patients can not find affordable therapy when they return home.
The new 240 square-meter center provides traditional Chinese acupuncture, massage, physical therapy, physiotherapy, electrotherapy and medical exercise-based techniques to help patients with neurological and autoimmune diseases such as ataxia, multiple sclerosis, cardiovascular disease, spinal cord injuries and autoimmune disorders, among others.
Beike Biotech Launches New International Stem Cell Venture
Saturday, 12 June 2010 15:22
"Beike Holdings Limited", a Strategic Joint Venture With Bangkok-Based SiriCell Technologies, Inc., Will Support the Rapid Clinical Translation of Stem Cell Therapies & Regulatory Approval Outside of China. Alex Moffett, Dr. Sean Hu, and Dato' KK Loh at Beike Holdings Announcement
SHENZHEN, China, June 10 /PRNewswire-Asia/ -- Shenzhen Beike Biotechnology Co. Ltd. ("Beike"), China's leading stem cell research and regenerative medicine company, announced the formation of Beike Holdings Limited ("Beike Holdings") a joint venture with Bangkok-based SiriCell Technologies, Inc. Beike Holdings, which is headquartered in Bangkok, Thailand, will focus primarily on the establishment of new international subsidiaries and the development of collaborative hospital partnerships with Southeast Asia's leading healthcare providers.
The joint venture is actively constructing a regional network of world class cGMP stem cell manufacturing labs, distribution centers and storage banks to service and support its hospital training and clinical advisory services.
Beike's stem cells have been shown to be safe and effective in therapies based on direct clinical observation in the hospital setting. Beike Holdings will fund and oversee a series of comprehensive, multi-centered, adaptive Phase 1 and 2 clinical trials to advance the ongoing clinical validations of the safety and efficacy of Beike's stem cell therapies to patients throughout Southeast Asia.
In an effort to expand the availability of Beike's stem cell products for therapeutic applications to hospitals throughout the region, Beike Holdings is establishing subsidiary operations in major Asian urban centers. In the coming weeks Beike Holdings will announce a series of agreements with leading hospitals in Thailand, Malaysia, and the Philippines.
What was once a country hiding behind a wall and insistent on isolation from the West has now become the second largest economy in the world (behind the US). Thousands of foreigners now call major Chinese cities home and many central areas of large cities such as Beijing, Qingdao, Shanghai, and Shenzhen now look and feel like their Western equivalents.
Foreign brands and restaurants, such as McDonalds, KFC, Mercedes, Wal-Mart, Apple Computers, Coke and Pepsi, etc., have been immensely popular for the last ten years. China has a long history of interaction with the West inside of the country’s borders. Shanghai has the French Concession, the British governed Hong Kong until 1997, and Qingdao maintained a large 20th century population of Germans.
This is not to say that China isn’t its own country without its own culture. There are very real cultural and geographic differences that might take patients some time to get accustomed to. Traffic flow is fast and sometimes aggressive, popular public areas can be very crowded, and there are sometimes just as many gray-sky days as there are blue-sky days.
And depending on your location, you might get some stares from the locals as you walk by. But for every stare you get on the street, you will also get a smile from the shop person or restaurant waitress. If there is one remark we have heard more than any other from patients, it is how amazingly nice the people are.
We fully understand that it is impossible to know exactly what a new place will be like until you actually experience it in person. But we are here to help and provide and details necessary to help you decide if China is a place worth visit to receive treatment.